+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06360627

Evaluation of Ultra Low Dose CT Scans Using Iomeron 400 Contrast for Lung Conditions

Led by University of Zurich · Updated on 2024-04-11

100

Participants Needed

1

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial evaluates ultra low dose computed tomography CT scan protocols and the use of Iomeron 400 contrast in photon-counting detector CT PCD-CT imaging. It focuses on participants needing CT scans for lung conditions such as pulmonary nodules, pneumonia, lung embolism, or lung cancer. The study aims to compare radiation dose reduction while maintaining image quality in these scans. Participants will undergo either a standard low dose CT scan or an ultra low dose CT scan using the new PCD-CT technology with Iomeron 400 contrast. The study is non-randomized and open-label, meaning participants know which scan protocol they receive. The primary focus is on dose reduction and image quality over about one year of follow-up. During the study, participants will have chest CT scans to detect or monitor lung issues. Researchers will assess radiation dose reduction achieved by the new scanner and monitor image quality stability during reduced dose scans. The total study duration is approximately one year, and safety and scan effectiveness are tracked throughout this period.

CONDITIONS

Brief Title

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here